SLC28 genes and concentrative nucleoside transporter (CNT) proteins

Xenobiotica

Volumn 38, Issue 7-8, 2008, Pages 972-994

  Pastor Anglada, M ^a   Cano Soldado, P ^a   Errasti Murugarren, E ^a   Casado, F J ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adenosine; Anticancer; Antiviral therapeutics; Concentrative nucleoside transporter (CNT); Nucleoside transporters; Pharmacogenetics

Indexed keywords

3 DEAZAURIDINE; CLADRIBINE; CLOFARABINE; CYTARABINE; DIDANOSINE; DOXIFLURIDINE; FLOXURIDINE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; LAMIVUDINE; MERCAPTOPURINE; NUCLEOSIDE TRANSPORTER; RIBAVIRIN; STAVUDINE; TIAZOFURIN; TIOGUANINE; TROXACITABINE; ZALCITABINE; ZIDOVUDINE;

DRUG TRANSPORT; HUMAN; PHARMACOGENETICS; PHYSIOLOGY; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW;

EID: 48749096696     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802069096     Document Type: Review

References (120)

1. Aymerich I, Foufelle F, Ferre P, Casado FJ, Pastor-Anglada M. 2006. Extracellular adenosine activates AMP-dependent protein kinase (AMPK). Journal of Cell Science 119(Pt 8):1612-1621.
2. Aymerich I, Pastor-Anglada M, Casado FJ. 2004. Long term endocrine regulation of nucleoside transporters in rat intestinal epithelial cells. Journal of General Physiology 124(5):505-512.
3. Badagnani I, Chan W, Castro RA, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, et al. 2005. Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3). Pharmacogenomics Journal 5(3):157-165.
4. Baldwin SA, Mackey JR, Cass CE, Young JD. 1999. Nucleoside transporters: Molecular biology and implications for therapeutic development. Molecular Medicine Today 5(5):216-224.
5. Balzarini J. 2000. Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors. Pharmacology and Therapy 87(2-3):175-187.
6. Cano-Soldado P, Lorrayoz IM, Molina-Arcas M, Casado FJ, Martinez-Picado J, Lostao MP, Pastor-Anglada M. 2004. Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antiviral Therapy 9(6):993-1002.
7. Cano-Soldado P, Molina-Arcas M, Alguero B, Larrayoz I, Lostao MP, Grandas A, Casado FJ, Pastor-Anglada M. 2008. Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells. Biochemistry and Pharmacology 75(3):639-648.
8. Chang C, Swaan PW, Ngo LY, Lum PY, Patil SD, Unadkat JD. 2004. Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. Molecular Pharmacology 65(3):558-570.
9. Che M, Ortiz DF, Arias IM. 1995. Primary structure and functional expression of a cDNA encoding the bile canalicular, purine-specific Na(+)-nucleoside cotransporter. Journal of Biology and Chemistry 270(23):13596-13599.
10. Clarke ML, Damaraju VL, Zhang J, Mowles D, Tackaberry T, Lang T, Smith KM, Young JD, Tomkinson B, Cass CE. 2006. The role of human nucleoside transporters in cellular uptake of 4′-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine. Molecular Pharmacology 70(1):303-310.
11. Craig JE, Zhang Y, Gallagher MP. 1994. Cloning of the nupC gene of Escherichia coli encoding a nucleoside transport system, and identification of an adjacent insertion element, IS 186. Molecular Microbiology 11(6):1159-1168.
12. Damaraju S, Zhang J, Visser F, Tackaberry T, Dufour J, Smith KM, Slugoski M, Ritzel MW, Baldwin SA, Young JD, et al. 2005a. Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene. Pharmacogenetics and Genomics 15(3):173-182.
13. Damaraju VL, Visser F, Zhang J, Mowles D, Ng AM, Young JD, Jayaram HN, Cass CE. 2005b. Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside. Molecular Pharmacology 67(1):273-279.
14. Daniel H. 2004. Molecular and integrative physiology of intestinal peptide transport. Annual Reviews in Physiology 66:361-384.
15. Del Santo B, Tarafa G, Felipe A, Casado FJ, Pastor-Anglada M. 2001. Developmental regulation of the concentrative nucleoside transporters CNT1 and CNT2 in rat liver. Journal of Hepatology 34(6):873-880.
16. Donofrio J, Coleman MS, Hutton JJ, Daoud A, Lampkin B, Dyminski J. 1978. Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease. Journal of Clinical Investigation 62(4):884-887.
17. Dragan Y, Valdes R, Gomez-Angelats M, Felipe A, Javier Casado F, Pitot H, Pastor-Anglada M. 2000. Selective loss of nucleoside carrier expression in rat hepatocarcinomas. Hepatology 32(2):239-246.
18. Dresser MJ, Leabman MK, Giacomini KM. 2001. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. Journal of Pharmaceutical Science 90(4):397-421.
19. Duflot S, Calvo M, Casado FJ, Enrich C, Pastor-Anglada M. 2002. Concentrative nucleoside transporter (rCNT1) is targeted to the apical membrane through the hepatic transcytotic pathway. Experimental Cell Research 281(1):77-85.
20. Duflot S, Riera B, Fernandez-Veledo S, Casado V, Norman RI, Casado FJ, Lluis C, Franco R, Pastor-Anglada M. 2004. ATP-sensitive K(+) channels regulate the concentrative adenosine transporter CNT2 following activation by A(1) adenosine receptors. Molecular Cell Biology 24(7):2710-2719.
21. Emami S, Kumar P, Yang J, Kresolic Z, Paproski R, Cass C, McEwan AJ, Wiebe LI. 2007. Synthesis, transportability and hypoxiaselective binding of 1-beta-D-(5-deoxy-5-fluororibofuranosyl)-2-nitroimidazole (beta-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA. Journal of Pharmacy and Pharmaceutical Science 10(2):237-245.
22. Errasti-Murugarren E, Cano-Soldado P, Pastor-Anglada M, Casado FJ. 2008. Functional characterization of a nucleoside-derived drug transporter variant (hCNT3C602R) showing altered sodium-binding capacity. Molecular Pharmacology 73(2):379-386.
23. Errasti-Murugarren E, Pastor-Anglada M, Casado FJ. 2007. Role of CNT3 in the transepithelial flux of nucleosides and nucleoside-derived drugs. Journal of Physiology 582(Pt 3):1249-1260.
24. Farre X, Guillen-Gomez E, Sanchez L, Hardisson D, Plaza Y, Lloberas J, Casado FJ, Palacios J, Pastor-Anglada M. 2004. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. International Journal of Cancer 112(6):959-966.
25. +-dependent nucleoside transport in liver: two different isoforms from the same gene family are expressed in liver cells. Biochemistry Journal 330(Pt 2):997-1001.
26. Fernandez-Veledo S, Jover R, Casado FJ, Gomez-Lechon MJ, Pastor-Anglada M. 2007. Transcription factors involved in the expression of SLC28 genes in human liver parenchymal cells. Biochemical and Biophysical Research Communications 353(2):381-388.
27. Fernandez-Veledo S, Valdes R, Wallenius V, Casado FJ, Pastor-Anglada M. 2004. Up-regulation of the high-affinity pyrimidine-preferring nucleoside transporter concentrative nucleoside transporter 1 by tumor necrosis factor-alpha and interleukin-6 in liver parenchymal cells. Journal of Hepatology 41(4):538-544.
28. Ferraris RP. 2001. Dietary and developmental regulation of intestinal sugar transport. Biochemistry Journal 360(Pt 2):265-276.
29. +-dependent, guanosine-specific, nitrobenzylthioinosine-sensitive transporter in acute promyelocytic leukemia cells. Journal of Biology and Chemistry 272(29):18026-18032.
30. Fotoohi AK, Lindqvist M, Peterson C, Albertioni F. 2006. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochemical and Biophysical Research Communications 343(1):208-215.
31. Galmarini CM. 2002. Nucleoside analogues in cancer treatment. Electronic Journal of Oncology 1:22-32.
32. Galmarini CM, Mackey JR, Dumontet C. 2001. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15(6):875-890.
33. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. 2003. Nucleoside transporter profiles in human pancreatic cancer cells: Role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clinical Cancer Research 9(13):5000-5008.
34. Gloeckner-Hofmann K, Guillen-Gomez E, Schmidtgen C, Porstmann R, Ziegler R, Stoss O, Casado FJ, Ruschoff J, Pastor-Anglada M. 2006. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology 70(3):238-244.
35. Gourdeau H, Clarke ML, Ouellet F, Mowles D, Selner M, Richard A, Lee N, Mackey JR, Young JD, Jolivet J, et al. 2001. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Research 61(19):7217-7224.
36. Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, Tse CM, Hayashi J, Unadkat JD. 2007. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 293(5):R1809-R1822.
37. Graham KA, Leithoff J, Coe IR, Mowles D, Mackey JR, Young JD, Cass CE. 2000. Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1. Nucleosides, Nucleotides and Nucleic Acids 19(1-2):415-434.
38. Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, Huang CC, Kawamoto M, Johns SJ, Stryke D, et al. 2004a. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Molecular Pharmacology 65(3):512-519.
39. Gray JH, Owen RP, Giacomini KM. 2004b. The concentrative nucleoside transporter family, SLC28. Pflugers Archives 447(5):728-734.
40. Griffith DA, Jarvis SM. 1996. Nucleoside and nucleobase transport systems of mammalian cells. Biochimica et Biophysica Acta 1286(3):153-181.
41. Guallar JP, Cano-Soldado P, Aymerich I, Domingo JC, Alegre M, Domingo P, Villarroya F, Javier Casado F, Giralt M, Pastor-Anglada M. 2007. Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients. Antiviral Therapy 12(6):853-863.
42. Gutierrez MM, Brett CM, Ott RJ, Hui AC, Giacomini KM. 1992. Nucleoside transport in brush border membrane vesicles from human kidney. Biochimica et Biophysica Acta 1105(1):1-9.
43. Gutierrez MM, Giacomini KM. 1993. Substrate selectivity, potential sensitivity and stoichiometry of Na(+)-nucleoside transport in brush border membrane vesicles from human kidney. Biochimica et Biophysica Acta 1149(2):202-208.
44. +-nucleoside cotransporter rCNT1. Journal of Biology and Chemistry 276(30):27981-27988.
45. Hansen PB, Schnermann J. 2003. Vasoconstrictor and vasodilator effects of adenosine in the kidney. American Journal of Physiology and Renal Physiology 285(4):F590-F599.
46. Hu H, Endres CJ, Chang C, Umapathy NS, Lee EW, Fei YJ, Itagaki S, Swaan PW, Ganapathy V, Unadkat JD. 2006. Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3). Molecular Pharmacology 69(5):1542-1553.
47. Huang QQ, Yao SY, Ritzel MW, Paterson AR, Cass CE, Young JD. 1994. Cloning and functional expression of a complementary DNA encoding a mammalian nucleoside transport protein. Journal of Biology and Chemistry 269(27):17757-17760.
48. Jordheim LP, Dumontet C. 2007. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochimica et Biophysica Acta 1776(2):138-159.
49. Kato R, Maeda T, Akaike T, Tamai I. 2005. Nucleoside transport at the blood-testis barrier studied with primary-cultured Sertoli cells. Journal of Pharmacology and Experimental Therapy 312(2):601-608.
50. King AE, Ackley MA, Cass CE, Young JD, Baldwin SA. 2006. Nucleoside transporters: From scavengers to novel therapeutic targets. Trends in Pharmacology Science 27(8):416-425.
51. King K, Damaraju V, Vickers M, Yao S, Lang T, Tackaberry T, Mowles D, Ng A, Young J, Cass C. 2005. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Molecular Pharmacology, 69(1):346-353.
52. Kong W, Engel K, Wang J. 2004. Mammalian nucleoside transporters. Current Drug Metabolism 5(1):63-84.
53. Lai Y, Bakken AH, Unadkat JD. 2002. Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells. Localization and vectorial transport studies. Journal of Biology and Chemistry 277(40):37711-37717.
54. Lai Y, Lee EW, Ton CC, Vijay S, Zhang H, Unadkat JD. 2005. Conserved residues F316 and G476 in the concentrative nucleoside transporter 1 (hCNT1) affect guanosine sensitivity and membrane expression, respectively. American Journal of Physiology and Cell Physiology 288(1):C39-C45.
55. Lang TT, Selner M, Young JD, Cass CE. 2001. Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. Molecular Pharmacology 60(5):1143-1152.
56. Lang TT, Young JD, Cass CE. 2004. Interactions of nucleoside analogs, caffeine, and nicotine with human concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line. Molecular Pharmacology 65(4):925-933.
57. Larrayoz IM, Casado FJ, Pastor-Anglada M, Lostao MP. 2004. Electrophysiological characterization of the human Na(+)/nucleoside cotransporter 1 (hCNT1) and role of adenosine on hCNT1 function. Journal of Biology and Chemistry 279(10):8999-9007.
58. +/nucleoside co-transporter (CaCNT) from Candida albicans, a fungal member of the concentrative nucleoside transporter (CNT) family of membrane proteins. Yeast 20(8):661-675.
59. Loewen SK, Ng AM, Yao SY, Cass CE, Baldwin SA, Young JD. 1999. Identification of amino acid residues responsible for the pyrimidine and purine nucleoside specificities of human concentrative Na(+) nucleoside cotransporters hCNT1 and hCNT2. Journal of Biology and Chemistry 274(35):24475-24484.
60. Loewen SK, Yao SY, Slugoski MD, Mohabir NN, Turner RJ, Mackey JR, Weiner JH, Gallagher MP, Henderson PJ, Baldwin SA, et al. 2004. Transport of physiological nucleosides and anti-viral and anti-neoplastic nucleoside drugs by recombinant Escherichia coli nucleoside-H(+) cotransporter (NupC) produced in Xenopus laevis oocytes. Molecular Membrane Biology 21(1):1-10.
61. Lu H, Chen C, Klaassen C. 2004. Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. Drug Metabolism and Disposition 32(12):1455-1461.
62. Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L, Glubrecht D, Jewell LD, Lai R, Lang T, et al. 2005. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): Identification of fludarabine-sensitive and -insensitive populations. Blood 105(2):767-774.
63. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young JD. 1999. Gemcitabine transport in Xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. Journal of the National Cancer Institute 91(21):1876-1881.
64. Mangravite LM, Badagnani I, Giacomini KM. 2003. Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. European Journal of Pharmacology 479(1-3):269-281.
65. Mangravite LM, Giacomini KM. 2003. Sorting of rat SPNT in renal epithelium is independent of N-glycosylation. Pharmacology Research 20(2):319-323.
66. Mangravite LM, Lipschutz JH, Mostov KE, Giacomini KM. 2001. Localization of GFP-tagged concentrative nucleoside transporters in a renal polarized epithelial cell line. American Journal of Physiology and Renal Physiology 280(5):F879-F885.
67. Mata JF, Garcia-Manteiga JM, Lostao MP, Fernandez-Veledo S, Guillen-Gomez E, Larrayoz IM, Lloberas J, Casado FJ, Pastor-Anglada M. 2001. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Molecular Pharmacology 59(6):1542-1548.
68. Nagase K, Tomi M, Tachikawa M, Hosoya K. 2006. Functional and molecular characterization of adenosine transport at the rat inner blood-retinal barrier. Biochimica et Biophysica Acta 1758(1):13-19.
69. Ngo LY, Patil SD, Unadkat JD. 2001. Ontogenic and longitudinal activity of Na(+)-nucleoside transporters in the human intestine. American Journal of Physiology and Gastrointestinal Liver Physiology 280(3):G475-G481.
70. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, et al. 2003. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clinical Pharmacology and Therapy 73(6):554-565.
71. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. 2002. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele frequencies in the Japanese population and functional analysis. Journal of Pharmacology and Experimental Therapy 302(2):804-813.
72. Owen RP, Badagnani I, Giacomini KM. 2006. Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2. Journal of Biology and Chemistry 281(36):26675-26682.
73. Owen RP, Gray JH, Taylor TR, Carlson EJ, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Giacomini KM. 2005. Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenetics and Genomics 15(2):83-90.
74. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larrayoz I, Martinez-Picado J, Casado FJ. 2005. Cell entry and export of nucleoside analogues. Virus Research 107(2):151-164.
75. Pastor-Anglada M, Casado FJ. 2006. Role of nucleoside transporters SLC28 and SLC29 in cancer chemotherapy. In: Godefridus JP, editor. Deoxynucleoside analogs in cancer therapy. Totowa, NJ: Human. pp 1-28.
76. Pastor-Anglada M, Felipe A, Casado FJ. 1998. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Trends in Pharmacology Science 19(10):424-430.
77. Patching SG, Baldwin SA, Baldwin AD, Young JD, Gallagher MP, Henderson PJ, Herbert RB. 2005. The nucleoside transport proteins, NupC and NupG, from Escherichia coli: specific structural motifs necessary for the binding of ligands. Organic and Biomolecular Chemistry 3(3):462-470.
78. +-nucleoside transporters. Cancer Chemotherapy and Pharmacology 46(5):394-402.
79. Redzic ZB, Biringer J, Barnes K, Baldwin SA, Al-Sarraf H, Nicola PA, Young JD, Cass CE, Barrand MA, Hladky SB. 2005. Polarized distribution of nucleoside transporters in rat brain endothelial and choroid plexus epithelial cells. Journal of Neurochemistry 94(5):1420-1426.
80. Ribelayga C, Mangel SC. 2005. A circadian clock and light/dark adaptation differentially regulate adenosine in the mammalian retina. Journal of Neuroscience 25(1):215-222.
81. +-dependent nucleoside transporter (CNT) family: Identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Molecular Membrane Biology 18(1):65-72.
82. +- nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Journal of Biology and Chemistry 276(4):2914-2927.
83. +-nucleoside cotransporter (hCNT1). American Journal of Physiology 272(2 Pt 1):C707-C714.
84. +/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Molecular Membrane Biology 15(4):203-211.
85. Rodriguez-Mulero S, Errasti-Murugarren E, Ballarin J, Felipe A, Doucet A, Casado FJ, Pastor-Anglada M. 2005. Expression of concentrative nucleoside transporters SLC28 (CNT1, CNT2, and CNT3) along the rat nephron: Effect of diabetes. Kidney International 68(2):665-672.
86. Saito H, Nishimura M, Shinano H, Makita H, Tsujino I, Shibuya E, Sato F, Miyamoto K, Kawakami Y. 1999. Plasma concentration of adenosine during normoxia and moderate hypoxia in humans. American Journal of Respiratory and Critical Care Medicine 159(3):1014-1018.
87. Savci V, Wurtman RJ. 1995. Effect of cytidine on membrane phospholipid synthesis in rat striatal slices. Journal of Neurochemistry 64(1):378-384.
88. Schachter JB, Yasuda RP, Wolfe BB. 1995. Adenosine receptor activation potentiates phosphoinositide hydrolysis and arachidonic acid release in DDT1-MF2 cells: putative interrelations. Cell Signal 7(7):659-668.
89. +- dependent nucleoside transporter (hSPNT1) in a mammalian expression system. Journal of Pharmacology and Experimental Therapy 289(3):1487-1491.
90. Shin HC, Landowski CP, Sun D, Vig BS, Kim I, Mittal S, Lane M, Rosania G, Drach JC, Amidon GL. 2003. Functional expression and characterization of a sodium-dependent nucleoside transporter hCNT2 cloned from human duodenum. Biochemical and Biophysical Research Communications 307(3):696-703.
91. Shryock JC, Belardinelli L. 1997. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. American Journal of Cardiology 79(12A):2-10.
92. Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, Kawamoto M, Johns SJ, DeYoung J, Carlson E, et al. 2003. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proceedings of the National Academy of Sciences, USA 100(10):5902-5907.
93. +/nucleoside cotransporter hCNT1 affect permeant selectivity and cation coupling. Biochemistry 46(6):1684-1693.
94. +-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes. Journal of Physiology 558(Pt 3):807-823.
95. +/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics. Journal of Biology and Chemistry 280(27):25436-25449.
96. Soler C, Felipe A, Garcia-Manteiga J, Serra M, Guillen-Gomez E, Casado FJ, MacLeod C, Modolell M, Pastor-Anglada M, Celada A. 2003. Interferon-gamma regulates nucleoside transport systems in macrophages through signal transduction and activator of transduction factor 1 (STAT1)-dependent and -independent signalling pathways. Biochemistry Journal 375(Pt 3):777-783.
97. Soler C, Garcia-Manteiga J, Valdes R, Xaus J, Comalada M, Casado FJ, Pastor-Anglada M, Celada A, Felipe A. 2001a. Macrophages require different nucleoside transport systems for proliferation and activation. FASEB Journal 15(11):1979-1988.
98. Soler C, Valdes R, Garcia-Manteiga J, Xaus J, Comalada M, Casado FJ, Modolell M, Nicholson B, MacLeod C, Felipe A, et al. 2001b. Lipopolysaccharide- induced apoptosis of macrophages determines the up-regulation of concentrative nucleoside transporters Cnt1 and Cnt2 through tumor necrosis factor-alpha-dependent and independent mechanisms. Journal of Biology and Chemistry 276(32):30043-30049.
99. Thomson S, Bao D, Deng A, Vallon V. 2000. Adenosine formed by 5′-nucleotidase mediates tubuloglomerular feedback. Journal of Clinical Investigation 106(2):289-298.
100. Tirona RG, Leake BF, Merino G, Kim RB. 2001. Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. Journal of Biology and Chemistry 276(38):35669-35675.
101. Toan SV, To KK, Leung GP, De Souza MO, Ward JL, Tse CM. 2003. Genomic organization and functional characterization of the human concentrative nucleoside transporter-3 isoform (hCNT3) expressed in mammalian cells. Pflugers Archives 447(2):195-204.
102. Valdes R, Casado FJ, Pastor-Anglada M. 2002. Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs. Biochemical and Biophysical Research Communications 296(3):575-579.
103. Valdes R, Fernandez-Veledo S, Aymerich I, Casado FJ, Pastor-Anglada M. 2006. TGF-beta transcriptionally activates the gene encoding the high-affinity adenosine transporter CNT2 in rat liver parenchymal cells. Cell and Molecular Life Science 63(21):2527-2537.
104. Valdes R, Ortega MA, Casado FJ, Felipe A, Gil A, Sanchez-Pozo A, Pastor-Anglada M. 2000. Nutritional regulation of nucleoside transporter expression in rat small intestine. Gastroenterology 119(6):1623-1630.
105. Walker UA, Auclair M, Lebrecht D, Kornprobst M, Capeau J, Caron M. 2006. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antiviral Therapy 11(1):25-34.
106. +-dependent nucleoside transporters. Journal of Biology and Chemistry 272(46):28845-28848.
107. +-nucleoside transporter. Molecular Pharmacology 55(2):234-240.
108. +-nucleoside transporter. Journal of Biology and Chemistry 274(4):2298-2302.
109. Wang J, Su SF, Dresser MJ, Schaner ME, Washington CB, Giacomini KM. 1997. Na(+)-dependent purine nucleoside transporter from human kidney: cloning and functional characterization. American Journal of Physiology 273(6 Pt 2):F1058-F1065.
110. Xiao G, Wang J, Tangen T, Giacomini KM. 2001. A novel proton-dependent nucleoside transporter, CeCNT3, from Caenorhabditis elegans. Molecular Pharmacology 59(2):339-348.
111. Yagil C, Katni G, Yagil Y. 1994. The effects of adenosine on transepithelial resistance and sodium uptake in the inner medullary collecting duct. Pflugers Archives 427(3-4):225-232.
112. Yamamoto T, Kuniki K, Takekuma Y, Hirano T, Iseki K, Sugawara M. 2007. Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. European Journal of Pharmacology 557(1):1-8.
113. +-nucleoside cotransporter (hfCNT) from the Pacific hagfish (Eptatretus stouti). American Journal of Physiology and Cell Physiology 283(1):C155-C168.
114. +/nucleoside cotransport by human concentrative nucleoside transporter 1 (hCNT1). Journal of Biology and Chemistry 282(42):30607-30617.
115. Young JD, Paterson AR, Henderson JF. 1985. Nucleoside transport and metabolism in erythrocytes from the Yucatan miniature pig. Evidence that inosine functions as an in vivo energy substrate. Biochimica et Biophysica Acta 842(2-3):214-224.
116. Zhang J, Smith KM, Tackaberry T, Visser F, Robins MJ, Nielsen LP, Nowak I, Karpinski E, Baldwin SA, Young JD, et al. 2005. Uridine binding and transportability determinants of human concentrative nucleoside transporters. Molecular Pharmacology 68(3):830-839.
117. Zhang J, Tackaberry T, Ritzel MW, Raborn T, Barron G, Baldwin SA, Young JD, Cass CE. 2006. Cysteine-accessibility analysis of transmembrane domains 11-13 of human concentrative nucleoside transporter 3. Biochemistry Journal 394(Pt 2):389-398.
118. Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE. 2007. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Reviews 26(1):85-110.
119. Zhang J, Visser F, Vickers MF, Lang T, Robins MJ, Nielsen LP, Nowak I, Baldwin SA, Young JD, Cass CE. 2003. Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in Saccharomyces cerevisiae. Molecular Pharmacology 64(6):1512-1520.
120. Zou AP, Nithipatikom K, Li PL, Cowley Jr. AW. 1999. Role of renal medullary adenosine in the control of blood flow and sodium excretion. American Journal of Physiology 276(3 Pt 2):R790-R798.